CLEC12A and acute myeloid leukemia: CLL1-CD33 CAR T-cells have not only demonstrated potent killing effects on AML cell lines in preclinical studies, but CLL1-CD33 compound (or dual expressing) CAR T-cells also induced remission in a 6-year-old child with r/r AML with complex karyotype [62].